Courtney V Fletcher1, Eugène Kroon2, Timothy Schacker3, Suteeraporn Pinyakorn4,5, Nicolas Chomont6, Suthat Chottanapund2, Peeriya Prueksakaew2, Khunthalee Benjapornpong2, Supranee Buranapraditkun7, Nittaya Phanuphak2, Jintanat Ananworanich8, Sandhya Vasan4,5, Denise Hsu4,5. 1. Antiviral Pharmacology Laboratory, UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA. 2. SEARCH, Institute of HIV Research and Innovation (IHRI), Bangkok, Thailand. 3. Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 4. U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland. 5. Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA. 6. Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Universite de Montréal, Montréal, Quebec, Canada. 7. Chulalongkorn University, Bangkok, Thailand. 8. Department of Global Health, Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: The ability of antiretroviral drugs to penetrate and suppress viral replication in tissue reservoir sites is critical for HIV remission. We evaluated antiretroviral concentrations in lymph nodes and their impact on HIV transcription. METHODS: Participants of the RV254/SEARCH010 Acute HIV Infection Cohort in Thailand were enrolled. Group 1 (n = 6) initiated and continued antiretrovirals with two nucleoside reverse transcriptase inhibitors (NRTIs), dolutegravir (DTG) and mar- aviroc (MVC). Group 2 (n = 12) initiated antiretrovirals with two NRTIs as well as efavirenz and were switched to two NRTIs as well as DTG. Antiretroviral concentrations were measured by mass spectroscopy. HIV RNA+ and DNA+ cells were measured by in-situ hybridization. RESULTS: All participants were MSM. At lymph node biopsy, all had plasma HIV RNA less than 20 copies/ml. Group 2 had longer durations of antiretroviral and DTG use (medians of 135 and 63 weeks, respectively) compared with Group 1 (median 44 weeks for both). TFV-DP, 3TC-TP, DTG and MVC were quantifiable in all lymph node samples from participants receiving those drugs versus carbovir-triphosphate (CBV-TP) in four out of 14. Median ratios of lymph node to peripheral blood concentrations were DTG, 0.014; MVC, 6.9; CBV-TP, 0.38; 3TC-TP, 0.32; and TFV-DP, 3.78. Median inhibitory quotients [ratios of lymph node concentrations to in-vitro inhibitory levels (IC50-or-90)] were DTG, 0.8; MVC, 38.8; CBV-TP, 0.5; 3TC- TP, 4.1; and TFV-DP, 1.8. Ongoing viral transcription was detected in lymph node of all participants. Median lymph node RNA+ cells were 71 350 versus 99 750 cells/g for Groups 1 and 2, respectively (P = 0.111). CONCLUSION: MVC has enhanced lymph node penetration and thereby may contribute to more complete viral suppression in the lymph node.
OBJECTIVE: The ability of antiretroviral drugs to penetrate and suppress viral replication in tissue reservoir sites is critical for HIV remission. We evaluated antiretroviral concentrations in lymph nodes and their impact on HIV transcription. METHODS: Participants of the RV254/SEARCH010 Acute HIV Infection Cohort in Thailand were enrolled. Group 1 (n = 6) initiated and continued antiretrovirals with two nucleoside reverse transcriptase inhibitors (NRTIs), dolutegravir (DTG) and mar- aviroc (MVC). Group 2 (n = 12) initiated antiretrovirals with two NRTIs as well as efavirenz and were switched to two NRTIs as well as DTG. Antiretroviral concentrations were measured by mass spectroscopy. HIV RNA+ and DNA+ cells were measured by in-situ hybridization. RESULTS: All participants were MSM. At lymph node biopsy, all had plasma HIV RNA less than 20 copies/ml. Group 2 had longer durations of antiretroviral and DTG use (medians of 135 and 63 weeks, respectively) compared with Group 1 (median 44 weeks for both). TFV-DP, 3TC-TP, DTG and MVC were quantifiable in all lymph node samples from participants receiving those drugs versus carbovir-triphosphate (CBV-TP) in four out of 14. Median ratios of lymph node to peripheral blood concentrations were DTG, 0.014; MVC, 6.9; CBV-TP, 0.38; 3TC-TP, 0.32; and TFV-DP, 3.78. Median inhibitory quotients [ratios of lymph node concentrations to in-vitro inhibitory levels (IC50-or-90)] were DTG, 0.8; MVC, 38.8; CBV-TP, 0.5; 3TC- TP, 4.1; and TFV-DP, 1.8. Ongoing viral transcription was detected in lymph node of all participants. Median lymph node RNA+ cells were 71 350 versus 99 750 cells/g for Groups 1 and 2, respectively (P = 0.111). CONCLUSION: MVC has enhanced lymph node penetration and thereby may contribute to more complete viral suppression in the lymph node.
Authors: Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase Journal: Science Date: 1999-11-12 Impact factor: 47.728
Authors: Shetty Ravi Dyavar; Nagsen Gautam; Anthony T Podany; Lee C Winchester; Jonathan A Weinhold; Timothy M Mykris; Kayla M Campbell; Yazen Alnouti; Courtney V Fletcher Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Maria C Puertas; Marta Massanella; Josep M Llibre; Monica Ballestero; Maria J Buzon; Dan Ouchi; Anna Esteve; Jaume Boix; Christian Manzardo; Josep M Miró; Josep M Gatell; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado Journal: AIDS Date: 2014-01-28 Impact factor: 4.177
Authors: Meghan Rothenberger; Krystelle Nganou-Makamdop; Cissy Kityo; Francis Ssali; Jeffrey G Chipman; Gregory J Beilman; Torfi Hoskuldsson; Jodi Anderson; Jake Jasurda; Thomas E Schmidt; Samuel P Calisto; Hope Pearson; Thomas Reimann; Caitlin David; Katherine Perkey; Peter Southern; Steve Wietgrefe; Erika Helgeson; Cavan Reilly; Ashley T Haase; Daniel C Douek; Courtney V Fletcher; Timothy W Schacker Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731